SynthesisBMC infectious diseases2026
Edwardsiella tarda infections in humans: a systematic review of reported cases and clinical outcomes.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEdwardsiella tarda, a rare human pathogen in the Enterobacteriaceae family, primarily inhabits aquatic environments and infects various animals. Human infections are uncommon but can lead to severe clinical outcomes. This systematic review aims to consolidate and analyze reported human cases of E. tarda infection.
methodsA comprehensive search was conducted across PubMed, Scopus, Embase, and Web of Science databases for studies published between January 2000 and October 2025.
resultsAfter applying exclusion criteria, 59 unique case reports were included. Cases spanned both genders, predominantly affecting older adults, with Japan reporting the highest number. A history of seafood consumption or contact with aquatic animals was common. Clinical presentations varied, though fever and abdominal pain were most frequent. Laboratory findings typically revealed elevated C-reactive protein and leukocytosis. Treatment regimens included antibiotics such as meropenem, ceftriaxone, ampicillin, metronidazole, and levofloxacin, the most frequently used.
conclusionsDespite its rarity, E. tarda can cause life-threatening infections. Awareness among clinicians regarding risk factors, diagnostic methods-particularly culture-based identification-and timely antibiotic therapy is crucial for improved outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.